A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE-BRAVE I)

The reason for this study is to see how effective and safe the study drug known as baricitinib is in participants with systemic lupus erythematosus (SLE).

Trial Summary

Age Range
≥18 years
Conditions the trial is for
What the trial is testing?
Could I receive a Placebo?
Yes
Enrollment Goal
830
Trial Dates
Aug 2, 2018 - Mar 9, 2022
How long will I be in the trial?
The study will last up to 62 weeks and may include up to 17 visits.
Trial Phase
III

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.